ACET
Adicet Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.59
+1.70%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | 25.0M |
| Cost of Revenue | 1.3M | 6.4M | — | — | — |
| Gross Profit | (1.3M) | (6.4M) | — | — | 25.0M |
| Operating Expenses | |||||
| R&D Expense | 83.8M | 99.1M | 99.3M | 106.0M | 71.2M |
| SG&A Expense | 19.9M | 23.0M | 28.3M | 26.5M | 26.3M |
| General & Admin Expense | 19.9M | 23.0M | 28.3M | 26.5M | 26.3M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (1.3M) | (6.4M) | — | 19.5M | — |
| Total Operating Expenses | 102.4M | 115.7M | 127.6M | 152.0M | 97.5M |
| Cost and Expenses | 103.7M | 122.1M | 127.6M | 152.0M | 97.5M |
| Operating Income (EBIT) | (103.7M) | (122.1M) | (127.6M) | (152.0M) | (72.6M) |
| Non-Operating | |||||
| Interest Income | 5.2M | 5.8M | 10.7M | 10.0M | 3.8M |
| Interest Expense | 81.0K | 36.0K | 4.0K | 25.0K | 80.0K |
| Net Interest Income | 5.1M | 5.7M | 10.7M | 10.0M | 3.7M |
| Other Non-Op Income/Expense | 4.9M | 5.3M | 10.5M | 9.4M | 2.8M |
| Non-Operating Income (excl Interest) | (5.0M) | (5.3M) | (10.5M) | (9.4M) | (2.8M) |
| EBT (Pre-Tax Income) | (98.8M) | (116.8M) | (117.1M) | (142.7M) | (69.8M) |
| Income Tax Expense | 143.0K | — | — | — | — |
| Bottom Line | |||||
| Net Income | (99.0M) | (116.8M) | (117.1M) | (142.7M) | (69.8M) |
| Earnings from Cont. Ops | (99.0M) | (116.8M) | (117.1M) | (142.7M) | (69.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (99.0M) | (116.8M) | (117.1M) | (142.7M) | (69.8M) |
| Per Share | |||||
| Basic EPS | ($11.45) | ($16.95) | ($21.28) | ($52.96) | ($27.20) |
| Diluted EPS | ($11.45) | ($16.95) | ($21.28) | ($52.96) | ($27.20) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $9.73 |
| Shares | |||||
| Basic Shares Outstanding | 10.7M | 6.9M | 5.5M | 2.7M | 2.6M |
| Diluted Shares Outstanding | 10.7M | 6.9M | 5.5M | 2.7M | 2.6M |
| Profitability Metrics | |||||
| EBITDA | (91.8M) | (110.4M) | (110.7M) | (136.5M) | (64.7M) |
| D&A | 6.9M | 6.4M | 6.5M | 6.1M | 5.0M |
| EBIT | (98.8M) | (116.8M) | (117.1M) | (142.6M) | (69.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026